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Background: Currently, sharing of drug paraphernalia is the main form of HCV transmission worldwide. In South
America, consistent findings indicate that shared sniffing equipment is an important factor in the spread of HCV
among non-injecting drug users. Epidemiological data on the status of HCV infection in illicit drug users in the
Amazon region are scarce, although reports of clinical cases of hepatitis or pathologies associated with HCV
infection in other population groups are numerous. Thereby, this study investigated the prevalence, genotype
frequency, and epidemiological factors associated with HCV infection in non-injecting drug users in the state of
Pará, eastern Amazon.
Results: During 2008–2011, 300 non-injecting drug users attending drug-treatment centers participated in this
study. Most non-injecting drug users were male (63.7%). The mean age was 32.5 years. The non-injecting drugs
most consumed were: cannabis (15.6%), cocaine paste (21.3%), and oxi cocaine (25.7%). Tobacco (60.9%) and
alcohol (79.4%) were also commonly consumed. One hundred six (35.1%; CI 95%: 29.8 - 41.1) non-injecting drug
users presented anti-HCV antibodies by EIA. The HCV-RNA prevalence was 28.0% (95% CI: 20.6 - 35.8). Genotypes 1
(76.9%) and 3 (23.1%) of HCV have been identified. A multivariate analysis demonstrated that HCV infection was
independently associated with the following factors: “age (≥ 35 years)”, “tattoos”, “use of a needle or syringe sterilized
at home”, “shared use of drug paraphernalia”, “uses drugs for more than 5 years”, and “use of drugs everyday”.
Conclusions: This study revealed a high prevalence of HCV infection in non-injecting drug users, and most infections
are occasioned by genotype 1. Likely, HCV transmission is associated with the tattoos, the use of needle or syringe
sterilized at home by people over the age of 35 years, and sharing, time and frequency of use of non-injecting drugs.
These findings should serve as an incentive for the establishment of a program of Hepatitis C prevention and control
by the local public-health authorities in order to develop effective policies and strategies for contain the spread
of HCV infection.
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Currently, sharing of drug paraphernalia is the main
form of transmission of the hepatitis C virus (HCV)
worldwide. It is estimated that more than 60% of the
new cases of HCV infection recorded each year are
related to the use of illicit drugs, especially by injec-
tion [1]. The prevalence of HCV infection in illicit
drug users varies from 10% to 95%, reflecting the
presence or absence of specific risk factors, such as
the history of drug use, sharing of drug paraphernalia
(needles, syringes, pipes, cans, and so on), the num-
ber of partners present during shared use, detention
and the use of drugs in jail or prison, and the type of
consumption: inhaled or injected [2,3]. A number of
studies have shown that the sharing of drug parapher-
nalia is responsible for the spread of HCV among
both injecting drug users and non-injecting drug
users [2,4-6].
Recently in South America, consistent findings indi-
cate that shared sniffing equipment is relevant in an
important factor in the spread of HCV among non-
injecting drug users [7-9]. In Brazil, epidemiological
studies of HCV infection in non-injection drug user are
still rare. There are few Brazilian studies investigating
HCV infection in illicit drug users including both inject-
ing and non-injecting drug users. Their HCV prevalence
rates range from 5.8% to 36.2%. HCV genotype 1 pre-
dominated, while genotype 3 was the second most com-
mon in illicit-drug users in Brazil [9-14].
Epidemiological data on the status of HCV infection
in illicit-drug users in the Amazon are scarce, although
reports of clinical cases of hepatitis or pathologies asso-
ciated with HCV infection in other population groups
are numerous [15-18]. The Amazon region is the site of
most of the world production of cocaine and its deriv-
atives [19]. Commonly, the police authorities record
arrests and trafficking of cocaine and its derivatives in
the Brazilian portion of the Amazon region (northern
Brazil). Among the states that comprise the Brazilian
Amazon, the state of Pará has become known for inte-
grating various routes of trafficking cocaine and its
derivatives in Brazil and around the world. Currently,
most users of illicit drugs in Pará do not use injection
as the route of administration, and are infected with
HCV genotype 1 [9,18]. Research has suggested that
HCV infection is highly prevalent in non-injecting co-
caine users, and viral transmission is likely to be asso-
ciated with “shared use of paraphernalia”, “daily use of
cocaine”, and a “long history of cocaine use” [9]. Given
this, the aim of this study was to estimate the preva-
lence of HCV infection and the main genotypes circu-
lating among non-injecting drug users in the state of
Pará, and to assess the factors associated with HCV
infection in these subjects.Results
In total, 327 illicit drug users agreed to participate in the
study. However, twenty-seven patients had records of
injection drug use and were excluded from analysis. Ac-
cording to information provided by 300 non-injecting
drug users, this epidemiological study was developed.
Most non-injecting drug users were male (63.7%). The
mean age was 32.5 ± 10.3 years (median = 31 years).
None of non-injecting drug users considered themselves
to be ex-drug users (patients who reported that if they
left drug-treatment centers (DTC) at the time of the
interview, they would not resume using illicit drugs).
Several participants (49.1%) reported having consumed
more than one illicit drug during their lifetime. Thus,
illicit-drug users were grouped according to the drug
used most frequently. Drug preference was grouped into
seven categories: cannabis (15.6%), cocaine paste (21.3%),
cannabis and cocaine paste (11.7%), cocaine powder
(14.0%), cocaine powder and paste (0.7%), oxi cocaine
(25.7%), and crack cocaine (11.0%). Tobacco (60.9%)
and alcohol (79.4%) were also commonly consumed by
the subjects.
One hundred six (35.1%; CI 95%: 29.8 - 41.1) non-
injecting drug users presented anti-HCV antibodies by
EIA. Eighty-four (79.2%) of these 106 had HCV-RNA de-
tected by real-time PCR. The HCV-RNA prevalence
among patients was 28.0% (95% CI: 20.6 - 35.8). Further-
more, two hundred one (67.0%; CI 95%: 62.7 - 71.5) out
of 300 non-injecting drug users were found by EIA to
have anti-HIV antibodies. Sixty-three (31.3%; CI 95%:
26.2 - 36.2) of these 201 had anti-HCV antibodies detected
by EIA, and forty-nine (24.4%; CI 95%: 18.7 - 29.9) had
HCV-RNA detected by real-time PCR. The Table 1 shows
more characteristics of the non-injecting drug users in this
study. Using univariate analysis, several variables associ-
ated with HCV infection were identified: age (≥ 35 years),
surgery, tattoos, use of a needle or syringe sterilized at
home, shared use of drug paraphernalia, history of illicit
drug use, and frequency of illicit drug use (daily). How-
ever, the risk factors for HCV infection became clearer
only after multiple logistic regression analysis. Risk factors
for HCV infection among non-injecting drug users were:
age (≥ 35 years), tattoos, use of a needle or syringe steril-
ized at home, shared use of drug paraphernalia, history
of illicit drug use (more than 5 years), and frequency of
illicit drug use (daily) (Table 2). The Hosmer-Lemeshow
goodness-of-fit test showed a good fit for the final model
1 (HLχ
2 = 4.4; p = 0.6) and model 2 (HLχ
2 = 3.1, p = 0.7).
A total of 84 nucleotide sequences of the 5’ UTR of
the HCV were isolated, of which 62 (73.8%) were identi-
cal, so only one representative was maintained for the
alignment. HCV genotypes were identified employing
the model of Tamura-Nei adjusted by the parameters es-
timated through the PHYML program. The phylogenetic
Table 1 Demographic and epidemiological characteristics of non-injecting drug users attending private and public











Total 300 106 (35.3) 84 (28.0)
Mean age (years) 32.5 36.5 37.3
Age ≥ 35 years 114 (38.0) 63 (59.4) 4.1 (2.5 - 6.8) 44 (52.4) 2.3 (1.4 - 3.8)
Heterosexual 279 (93.0) 101 (95.3) 1.7 (0.6 - 4.9) 78 (92.9) 1.0 (0.4 - 2.6)
Anti-HIV+ 201 (67.0) 63 (59.4) 1.5 (0.9 - 2.4) 49 (58.3) 0.7 (0.4 - 1.1)
Supposed route of HCV infection
Family member or close friend infected with HCV 23 (7.7) 5 (4.7) 0.5 (0.2 - 1.3) 3 (3.5) 0.4 (0.1 - 1.2)
Recipient of blood transfusion 40 (13.3) 13 (12.5) 0.9 (0.4 - 1.8) 12 (14.3) 1.2 (0.5 - 2.3)
Surgery 139 (46.3) 58 (54.7) 1.7 (1.1 - 2.7) 44 (52.4) 1.5 (0.9 - 2.3)
Tattoos 177 (59.0) 81 (76.4) 3.3 (1.9 - 5.6) 76 (90.5) 10.9 (5.0 - 23.7)
Shared used of razor blades in the domestic environment 102 (34.0) 40 (37.7) 1.3 (0.8 - 2.1) 33 (39.3) 1.4 (0.8 - 2.3)
Shared used of blades in a barbershop/beauty salon 81 (27.0) 27 (25.5) 0.9 (0.5 - 1.5) 22 (26.2) 0.9 (0.5 - 1.7)
Use of a needle or syringe sterilized at home 72 (24.0) 33 (31.1) 1.8 (1.1 - 3.1) 28 (33.3) 2.0 (1.1 - 3.4)
Shared nail clippers 130 (43.3) 50 (47.2) 1.3 (0.8 - 2.1) 38 (42.2) 0.9 (0.5 - 1.5)
Invasive dental treatment 227 (75.7) 81 (76.4) 1.1 (0.6 - 1.9) 65 (77.4) 1.1 (0.6 - 2.1)
Shared use of drug paraphernalia 204 (68.0) 94 (88.7) 6.0 (3.1 - 11.6) 77 (91.7) 7.7 (3.4 - 17.5)
Use of drugs for more than 5 years 199 (66.3) 88 (83.0) 3.7 (2.0 - 6.5) 69 (82.1) 3.1 (1.6 - 5.7)
Use of drugs everyday 246 (82.0) 97 (91.5) 3.3 (1.5 - 6.9) 80 (95.2) 6.0 (2.1 - 17.2)
Have already been arrested in police station or prison 84 (28.0) 28 (33.3) 0.9 (0.5 - 1.4) 20 (23.8) 0.7 (0.4 - 1.3)
Use of drugs during detention 40 (13.3) 13 (32.5) 0.9 (0.4 - 1.8) 10 (11.9) 0.8 (0.4 - 1.8)
Unprotected sex 234 (78.0) 79 (74.5) 0.7 (0.4 - 1.3) 63 (75.0) 0.8 (0.4 - 1.4)
Sexual intercourse with another drug user 191 (63.7) 71 (67.0) 1.3 (0.8 - 2.1) 56 (66.7) 1.2 (0.4 -1.2)
Involvement in prostitution 157 (52.3) 50 (47.2) 0.7 (0.5 - 1.2) 36 (42.9) 0.7 (0.4 - 1.2)
More than 20 sexual partners over the past 2 years 138 (46.0) 44 (41.5) 0.8 (0.5 - 1.3) 35 (41.7) 0.8 (0.5 - 1.3)
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(76.9%, 64/78), followed by genotype 3 (23.1%, 20/78).
Although, the bootstrap values were not significant
(< 95.0), the phylogenetic tree indicated a predominance
of subtype 1b (50.0%, 42/84), followed by subtypes 1a
(26.2%, 22/84), 3a (13.1%, 11/78), and 3b (10.7%, 9/78)
(Figure 1).Table 2 Risk factors associated with HCV infection based on E
Risk factors M
OR (CI 95%)
Age (≥ 35 years) 2.3 (1.1 - 3.9)
Tattoos 2.8 (1.2 - 4.1)
Use of a needle or syringe sterilized at home 1.7 (1.1 - 3.4)
Shared use of drug paraphernalia 5.6 (1.8 - 9.5)
Uses drugs for more than 5 years 3.3 (1.9 - 4.5)
Use of drugs everyday 2.5 (1.4 - 3.7)Discussion
In Latin America, the overall prevalence of HCV infec-
tion is about 1.23%, however it varies from country to
country [20,21]. In Brazil, the prevalence of HCV infec-
tion is around 1.38%. In addition, significant differences
in the prevalence of infection and distribution of HCV
genotypes among Brazilian regions are reported. TheIA (model 1) and PCR (model 2) results
odel 1 Model 2
p-value OR (CI 95%) p-value
< 0.01 2.1 (1.2 - 4.4) 0.02
< 0.01 8.2 (3.9 - 17.2) < 0.01
0.02 2.3 (1.4 - 3.1) < 0.01
< 0.01 4.1 (1.9 - 8.4) < 0.01
< 0.01 3.0 (1.6 - 6.3) < 0.01
< 0.01 3.8 (1.1 - 6.5) 0.01
Figure 1 Maximum-likelihood phylogenetic tree derived from the alignment of 341 base pairs of the 5’ UTR of the Hepatitis C virus
detected in non-injecting drug users in Pará, eastern Amazon. The topological robustness of the tree was evaluated using a bootstrap analysis
with 1,000 replicates (bootstrap values of less than 50 are not shown). Drug users selected in this study can be identified by DU sample number
(+ number of sequences representing).
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http://www.virologyj.com/content/11/1/38northern of Brazil (Brazilian Amazon) stands out with the
highest prevalence of infections and higher frequency of
genotype 1 [20,22,23]. Among the risk groups for infec-
tion, illicit-drug users make up the main risk group for
HCV infection in Brazil [20,22].
A consensus now exists that the use of non-injected
drugs is a risk factor for the hepatitis C virus. Risk levels
appear to vary substantially by location [5,6,24-26]. HCV
prevalence in non-injecting drug users range from 2% to
38% in different parts of the world [3,8,11,27-29]. Epi-
demiological studies of illicit-drug users in the Northeast,
Midwest, South and Southeast regions of Brazil (includ-
ing both injecting and non-injecting drug users) haverecorded prevalence of HCV infection between 5% and
36% [9-14]. The HCV prevalence recorded in the
present study is within these estimated ranges, although
the rate of HCV infection among non-injecting drug
users in Pará was relatively high compared with the
rates obtained in similar populations in different parts
of the world, and extremely high and worrisome com-
pared to the reported rates of HCV infection in other
Brazilian regions. The marked prevalence of HCV-RNA
in the drug-user population studied here should serve
as an incentive for the establishment of a program of
Hepatitis C prevention and control by the local public-
health authorities. This program should include the use
Oliveira-Filho et al. Virology Journal 2014, 11:38 Page 5 of 8
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transmission of HCV infection. Given the important
consequence of this finding, more research on this topic is
warranted in eastern Amazon.
The mechanisms of HCV transmission among non-
injecting drug users are not well understood [3]. This
study identified six risk factors for HCV infection. Hav-
ing a tattoo was associated with HCV infection. Com-
monly, a tattoo is identified as a risk factor for HCV
infection in illicit-drug users [2,6,8]. Likely, this reflects
the lifestyle of illicit-drug users, which could include
greater exposure to HCV. Furthermore, the daily use of
drugs, paraphernalia sharing during drug use, and a long
history of drug use were also associated with HCV in-
fection in non-injecting drug users. Few studies have
reported the presence of HCV-RNA in the nasal secre-
tions of cocaine and crack users, indicating a possible
alternative route for the transmission of the virus – the
sharing of the paraphernalia used to consume these
drugs [4,30]. One hypothesis to account for these cases
involves intranasal transmission of HCV via contaminated
implements, requiring two primary virological precondi-
tions: the presence of blood and HCV in the nasal secre-
tions of intranasal drug users, and the transfer of blood
and HCV from the nasal cavity onto sniffing implements,
which are often shared by intranasal drug users [4,30]. In
Pará, HCV transmission may be associated with and pow-
ered by three risk factors: daily use of drugs, paraphernalia
sharing during drug use, and a long history of drug use
(more than 5 years). To prove this hypothesis, other,
more-specific studies will be needed in the future.
Other risk factors for HCV infection identified in this
study were age above 35 years, and use of a needle and
glass syringe sterilized at home. Administering injectable
medication without adequately sterilizing syringes or
needles has been the main cause of HCV transmission
worldwide, especially in developing countries [1,31,32].
In Brazil, disposable perforating and cutting materials
for health procedures began to be used on a large scale
during the second half of the 1980s. This situation, to-
gether with a lack of knowledge about HCV transmission,
likely accounts for the higher prevalence of infection
among Brazilians over 35, since transmission could have
occurred through sharing of inadequately sterilized syrin-
ges and needles in homes with individuals who were
asymptomatic and unaware that they were infected. Prob-
ably the risk factor “use of home-sterilized syringes and
needles” was partly responsible for the significantly higher
infection rate in the group older than 35 years. This may
also indicate that longer exposure to risk factors increases
the probability of infection with HCV. These two risk
factors for HCV infection have also been detected in
other Brazilian populations, including blood donors in
the Brazilian state of Pará [12,15,17,33].In Brazil, HCV genotype 1 predominates, followed by
genotypes 3 and 2 [23,34]. In the Brazilian Amazon, HCV
genotype 1 prevails in blood donors, health-care workers,
illicit-drug users, patients with chronic hematological dis-
ease, and patients undergoing hemodialysis [12,15,17,18].
The results of the present study were well within this
range, with a high frequency of HCV genotype 1 (1a and
1b) and the presence of genotype 3 (3a and 3b). This study
also showed that in a geographic area in which the pop-
ulations are predominantly infected with genotype 1, a
relatively high frequency of genotype 3 can also occur
[15-17,34]. This study concords with the finding of sev-
eral other studies that reported the existence of a sig-
nificant frequency of genotype 3 in illicit-drug users,
reflecting the intrinsic characteristic of network trans-
mission through sharing of illicit drugs and abuse of
their paraphernalia [11,12,18,35,36].
The present study has limitations that should be con-
sidered in the interpretation of results. No procedures
for identifying injection drug use, including those used
in this study, are foolproof. The number of non-injecting
drug users and their general characteristics in the state
of Pará are not actually known since drug use is an illicit
activity. For that reason, HCV infection was only investi-
gated among those non-injecting drug users enrolled in
private and public drug treatment centers during the study
period. On the other hand, given the scarcity of epidemio-
logical data about HCV infection among illicit-drug users
in the state do Pará, our results provide background infor-
mation for formulating policies and strategies for reducing
risk and damage associated to the use of illicit drugs. Fur-
thermore, the specific sexual behavior of illicit-drug users
in detention was not investigated. Some studies suggest
that illicit-drug use and sexual behavior during detention
may be associated with HCV infection [28,37]. Finally, the
5’ UTR contains sufficient variation to resolve HCV classi-
fications at the level of viral genotype. However, it is con-
served and limited in its ability to discriminate subtypes
within genotypes 1, 2, 3, 4, and 6 [38]. Thus, there is a
need for sequencing of other regions of the HCV genome
to improve the resolution of viral subtypes.Conclusions
This study revealed a high prevalence of HCV infection
in non-injecting drug users. Genotype 1 has the highest
frequency, and also detected the genotype 3. Likely viral
transmission occurred by three mechanisms: (1) tattoos,
(2) sharing needles and glass syringes at home associated
with age over 35 years, and (3) a combination of shared
use of paraphernalia, daily use, and a long history of
non-injection drug use. These factors require special
attention from public-health authorities in the Amazon
region, in order to develop effective policies and strategies
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of non-injecting drug users.
Methods
Sample collection
This was a cross-sectional study conducted in private
and public DTC in nine municipalities in the Brazilian
state of Pará (Abaetetuba, Ananindeua, Belém, Benevides,
Bragança, Castanhal, Marituba, São Francisco do Pará,
and Vigia), eastern Amazon. Twenty-five (78.1%) of
the 32 DTC that existed during the study period col-
laborated with the research. These included DTC lo-
cated within 350 km by road from the Centro de
Hematologia e Hemoterapia do Pará (HEMOPA), Belém,
PA, Brazil. Each DTC was visited at a time scheduled by
the research team. The DTC had an average capacity of
15 patients. All patients who were at the center on the day
when the team visited participated voluntarily. This study
included participants who were using only non-injectable
drugs, and excluded participants aged below 18 years.
All data were collected from February 2008 to January
2011. The study was approved by the Research and Ethics
Committee of the Núcleo de Medicina Tropical of the
Universidade Federal do Pará, Brazil.
Testing
Blood (5 ml) was collected in sterile tubes, allowed to
clot, and centrifuged at room temperature. The result-
ing plasma samples were collected and stored at a
temperature below 10°C. After the end of the collection
period at each DTC, the samples were transported to
HEMOPA. The plasma was then tested for the presence
of anti-HCV antibodies by enzyme immunoassay (EIA).
The Murex anti-HCV version 4.0 (Kyalami, Gauteng,
South Africa) was used to measure anti-HCV antibody
levels. Nonreactive samples were considered negative
for HCV. Reactive sample by EIA were submitted to
RNA extraction, reverse transcription, and real-time PCR
with primers complementary to the conserved area of the
5’ UTR of HCV, as described elsewhere [17]. Furthermore,
the HIV/HCV co-infection was evaluated. All plasma col-
lected was tested for HIV antibody by EIA. The Murex
HIV-1.2.O (Saluggia, Vercelli, Italy) was used to measure
anti-HIV antibodies. All tests for diagnosis of viral infec-
tions were performed at the Laboratory of Cellular and
Molecular Biology of the HEMOPA.
Genotyping
Following the molecular screening for HCV infection
using real-time PCR, samples that were positive for
HCV-RNA were selected for the amplification of 5’ UTR
using nested PCR [39]. The amplified fragment was
sequenced in both directions using a Big Dye Cycle
Sequencing standard kit and the dideoxynucleotidechain terminator method in an ABI Prism 3130 system
(Applied Biosystems - Foster City, California, USA). All
the nucleotide sequences obtained were edited and aligned
using the BioEdit program [40]. The final alignment was
entered into the DnaSP program [41] for the identification
of identical nucleotide sequences. Nucleotide sequences
obtained from the NCBI were added to the alignment and
used for the construction of the phylogenetic tree and the
differentiation of the HCV genotypes, as described else-
where [18]. Nucleotide sequence data obtained in this
study are available in GenBank under the accession
numbers JN243906-JN243997.
Questionnaire and records
The identification of the factors associated with HCV
infection was based on the use of structured question-
naire (face-to-face interviews), in which the following
variables were determined: gender, age, close family or
friends with hepatitis C, recipient of blood transfusion,
had surgery during the subject’s lifetime, had invasive
dental treatment (root canal or tartar removal) during
the subject’s lifetime, tattoo, shared used of razor blades
in the domestic environment, shared used of blades in a
barbershop, beauty salon or similar environment, use of
a needle or syringe sterilized at home, shared nail clip-
pers, types of legal drugs used during the subject’s life-
time, total time of drug use, frequency of drug use,
shared use of drug paraphernalia (tubes, cans, pipes and
similar), have already been arrested in police station or
prison, use of drugs during detention in jails or prison,
sexual orientation, unprotected sex, sexual intercourse
with another drug user, involvement in prostitution, and
multiple sexual partners. Furthermore, DTC structured
admission records were reviewed to assess drug-use his-
tories. The records include data on drug preference,
length of drug use, sexual risk behavior, the main drugs
used and their routes of administration. When clients
enter treatment, each major part of the body - head,
trunk, extremities and so on is examined. If needle use in-
dications are identified, they are recorded in the client’s re-
cords. The information provided by participants through
the questionnaire was compared with the records stored
in DTC to identify and delete injecting drug users.
Statistical analysis
Wilson confidence intervals were constructed for the
infection prevalence estimates [42]. Simple and multiple
logistic regressions were done to assess the independent
effect of variables [33]. The fit of the final model was
assessed using the Hosmer-Lemeshow goodness-of-fit
test. Two definitions of HCV infection cases were used:
(i) anti-HCV positivity shown by EIA, and (ii) HCV-
RNA detection by real-time PCR. All statistical analyses
were carried out using PASW Statistics version 18.0.
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